|Bid||62.75 x 1400|
|Ask||62.85 x 4000|
|Day's Range||61.56 - 63.61|
|52 Week Range||60.32 - 79.61|
|Beta (3Y Monthly)||1.23|
|PE Ratio (TTM)||15.10|
|Earnings Date||May 2, 2019|
|Forward Dividend & Yield||2.52 (3.88%)|
|1y Target Est||81.35|
Learn how the marriage of science and technology is changing the world of medicine and creating some of the largest multinational biotechnology corporations.
Gilead Sciences, Inc. (GILD) announced today that its first quarter 2019 financial results will be released on Thursday, May 2, after the market closes. At 4:30 p.m. Eastern Time, Gilead’s management will host a conference call to discuss the company’s financial results for the first quarter 2019 and provide a business update.
With negative earnings revisions, the healthcare sector is expected to witness earnings growth of 1.8% in the first quarter, suggesting smooth trading for healthcare ETFs.
Share price of Novo Nordisk (NVO) has increased year to date on strong presence in the Diabetes Care market and a solid pipeline.
On CNBC's "Mad Money Lightning Round," Jim Cramer said he would wait for Arista Networks Inc (NYSE: ANET ) to come down before buying the stock. Cramer likes NVIDIA (NASDAQ: NVDA ). He loves ...
Gilead (GILD) collaborates with data-driven company, Insitro, to harness the power of computers to discover and develop therapies for treating NASH (fatty liver).
Gilead Sciences announced a collaboration Tuesday to use machine learning to seek new treatment options for a progressive liver disease. It will pay Insitro $15 million upfront for the deal.
At first glance, shares of Amgen (NASDAQ:AMGN) look quite volatile. Upon further inspection, though, the six-month range in AMGN stock is actually pretty tight -- and it's been getting even tighter, as the stock has spent much of 2019 gathering in tightening coil. This sets up for a potentially large move. This move can happen in either direction, with bulls hoping Amgen stock resolves higher. * 7 Stocks That Can Outperform for Years Source: Richard Masoner via Flickr There are a lot of considerations when it comes to pulling the trigger on a name like Amgen. It's not just the technicals, but also the dividend, its valuation and growth profile. Let's take a closer look, first with the charts. Trading AMGN Stock Click to EnlargeAMGN is not the kind of stock that traders are normally drawn to. That's more for the names like Advanced Micro Devices (NADSAQ:AMD), Tesla (NASDAQ:TSLA) and others. But that doesn't mean we can't trace the technicals on AMGN stock.InvestorPlace - Stock Market News, Stock Advice & Trading TipsAt the end of March, AMGN stock was showing weakness and threatening to break down from a short-term double-top. Fast-forward about two weeks and Amgen stock is above all of its major moving averages. While being rejected by downtrend resistance (black line), shares are hanging just below this mark. Could that set up a breakout?That's what I'm looking for in AMGN stock. A drop down to about $190 would give bulls a chance to initiate a position near the 20-day moving average and uptrend support. Whether the pullback is done here, near $193, or drops to $190, as long as support holds, it could give AMGN stock the energy it needs to push through resistance.On the upside, a push through $196 could eventually ignite Amgen up to $206. Shares put in a double-top at this level in the fourth quarter, so it wouldn't be surprising to see this area act as resistance on AMGN's first try. On the downside, watch for support from the 50-day moving average at $188 -- provided uptrend support does not buoy Amgen.Below that, and a drop into the low-$180s is possible. Valuing Amgen StockAmgen stock is looking better and better on the charts, but that doesn't mean there aren't things to like about its fundamentals.For starters, AMGN stock has a 3% dividend yield. Management gave a ~10% bump in December, following increases of ~15% in each of the last two years ago. While the company has experienced lower growth than the past few years, it's clear management is putting an emphasis on returning capital to investors.There's also the valuation, which stands at less than 14 times this year's earnings. There is a catch, though: While this is a below-market valuation, we have to consider it versus its peers as well as against Amgen's own growth profile. When compared to names like Celgene (NASDAQ:CELG), Bristol-Myers Squibb (NYSE:BMY) (who are in M&A discussions) and Gilead (NASDAQ:GILD), Amgen stock is expensive.These stocks trade at roughly 10 times earnings or less, so, at 13.7 times this year's earnings, Amgen looks less attractive. It would help if it had better growth, too. Analysts expect revenue to decline almost 4% this year and for earnings to fall about 2% year over year. That said, consensus expectations do call for a rebound in both metrics in 2020 while AMGN could always top expectations this year. After all, it has beat -- rather impressively, I might add -- top- and bottom-line expectations in each of the past four quarters. * 10 Stocks That Are Screaming Buys Right Now One last note, AMGN stock is actually trading at a discount compared to its five-year average valuation -- and that's not just the price-to-earnings ratio either. Amgen isn't perfect, but if shares are going to break out this year, I don't expect the valuation to inhibit that move.Bret Kenwell is the manager and author of Future Blue Chips and is on Twitter @BretKenwell. As of this writing, Bret Kenwell is long CELG. More From InvestorPlace * 2 Toxic Pot Stocks You Should Avoid * 7 Internet Stocks to Watch * 7 AI Stocks to Watch with Strong Long-Term Narratives * 10 Dow Jones Stocks Holding the Blue Chip Index Back Compare Brokers The post Why Amgen Stock Could Break Out to New Highs appeared first on InvestorPlace.
Aiming to generate fresh data to run through its machine learning system, a startup is embarking on a three-year collaboration with one of biotech's biggest players in the fatty liver disease known as NASH.
Gilead Sciences Inc said on Tuesday it will partner with privately held insitro to develop therapies for a fatty liver disease called non-alcoholic steatohepatitis (NASH), as the drugmaker tries to overcome its recent setback in developing NASH treatments. The firm - launched last year with investments from Alphabet Inc's Verily and GV among others - uses machine learning to help discover and develop drug candidates. The partnership comes two months after Gilead's experimental NASH drug selonsertib failed to meet its main goal in a late-stage study.
Gilead Sciences Inc. (GILD) and insitro announced today that the companies have entered into a strategic collaboration to discover and develop therapies for patients with nonalcoholic steatohepatitis (NASH). Under the terms of the three-year collaboration, insitro’s proprietary platform will be utilized to create disease models for NASH and discover targets that have an influence on clinical progression and regression of the disease. The insitro Human (ISH) platform applies machine learning, human genetics and functional genomics to generate and optimize unique in vitro models and drive therapeutic discovery and development.
in their efforts to help combat liver disease. The two companies said they will collaborate on clinical trials for medications for treating nonalcoholic steatohepatitis (NASH). "The intended clinical trial will be a proof of concept study," according to a press release from Gilead.
Both JPMorgan and Deloitte expect strong merger and acquisition activity ahead, and analysts believe that these stocks are likely targets.
Novo Nordisk and Gilead Sciences will join forces on a clinical trial combining drugs from the two pharmaceutical firms to treat a progressive fatty liver disease known as NASH. The clinical trial will be a study combining Novo Nordisk's semaglutide drug and Gilead's cilofexor and firsocostat for treatment of patients with Nonalcoholic steatohepatitis (NASH), Novo Nordisk, best known for its diabetes drugs, said on Friday.
Gilead Sciences, Inc. (GILD) and Novo Nordisk A/S (NASDAQ Copenhagen: NOVO B) today announced that the companies intend to collaborate on a clinical trial combining compounds from their respective pipelines in nonalcoholic steatohepatitis (NASH). The intended clinical trial will be a proof of concept study combining Novo Nordisk’s semaglutide (GLP-1 analogue) and Gilead’s cilofexor (FXR agonist) and firsocostat (ACC inhibitor) for the treatment of patients with NASH. The companies are also exploring the potential to collaborate on preclinical research to advance understanding of the disease.
Intercept Pharmaceuticals (ICPT) reports positive additional supportive data from its phase III REGENERATE study of obeticholic acid in patients with liver fibrosis due to NASH.
– Data Demonstrate Role of Gilead HCV Medicines in Difficult–to-Treat Patient Populations and in Real-World Settings –
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks hitting 52-week highs on April 10) Fulgent Genetics Inc (NASDAQ: FLGT ) Intuitive Surgical, ...